KalVista Pharmaceuticals, Inc. (KALV) Bundle
A Brief History of KalVista Pharmaceuticals, Inc. (KALV)
Founding and Early Years
Founding and Early Years
KalVista Pharmaceuticals, Inc. was founded in 2016, focusing on the development of treatments for diseases related to the metabolic and vascular systems. The company has its headquarters in Cambridge, Massachusetts. The initial public offering (IPO) took place on July 31, 2018, and KalVista raised approximately $30 million during this event by selling 2.5 million shares at an initial price of $12 per share.
Product Development Pipeline
KalVista's primary focus has been in developing oral therapies for diabetic macular edema (DME) and hereditary angioedema (HAE). The most notable drug candidates include:
- KV-101: A treatment for HAE, currently in Phase 3 trials as of Q4 2023.
- KV-201: Targeting DME, which completed Phase 2 trials in early 2023.
Financial Performance
As of the end of Q3 2023, KalVista reported revenue figures highlighting their financial growth:
| Year | Revenue ($ million) | Net Income ($ million) | R&D Expenses ($ million) |
|---|---|---|---|
| 2020 | 1.5 | -15.8 | 12.1 |
| 2021 | 2.3 | -18.5 | 14.3 |
| 2022 | 3.0 | -22.0 | 16.0 |
| 2023 | 4.5 | -20.1 | 18.5 |
Partnerships and Collaborations
KalVista has engaged in several key partnerships to enhance its development capabilities. Notably:
- Collaboration with Merck & Co. in 2020, focusing on co-developing KV-101.
- Partnership agreement with Amgen in 2021 for shared research on microvascular diseases.
Market Capitalization and Stock Performance
As of October 2023, the market capitalization of KalVista Pharmaceuticals is approximately $300 million. The stock price has exhibited volatility, ranging between $8 and $18 in the past year, reflecting market conditions and clinical trial outcomes.
Regulatory Milestones
KalVista has achieved significant regulatory milestones:
- Received FDA Fast Track Designation for KV-101 in January 2023.
- Awarded Orphan Drug Designation for KV-201 in March 2022.
Current Challenges and Future Outlook
As KalVista continues to navigate the competitive landscape of biopharmaceuticals, challenges remain regarding R&D funding and trial outcomes. Despite these challenges, industry analysts project a positive outlook if clinical trials yield favorable results.
A Who Owns KalVista Pharmaceuticals, Inc. (KALV)
Stock Ownership Breakdown
Stock Ownership Breakdown
The ownership of KalVista Pharmaceuticals, Inc. (KALV) can be divided into several categories: institutional ownership, insider ownership, and retail ownership. As of the last reported financial quarter in September 2023, the following statistics were available:
| Ownership Type | Percentage Ownership (%) | Number of Shares |
|---|---|---|
| Institutional Investors | 68.5 | 5,800,000 |
| Insider Ownership | 10.2 | 850,000 |
| Retail Investors | 21.3 | 1,800,000 |
Major Institutional Holders
KalVista Pharmaceuticals has several prominent institutional investors. Key institutions holding shares as of September 2023 include:
| Institution | Shares Held | Ownership Percentage (%) |
|---|---|---|
| The Vanguard Group, Inc. | 2,500,000 | 29.5 |
| BlackRock, Inc. | 1,800,000 | 21.3 |
| State Street Corporation | 1,200,000 | 14.2 |
| Swedbank Robur Fonder AB | 1,000,000 | 11.8 |
| JPMorgan Chase & Co. | 800,000 | 9.4 |
Insider Transactions
Insider ownership plays a significant role in corporate governance. The following table highlights recent insider transactions:
| Insider Name | Position | Shares Sold | Date of Transaction |
|---|---|---|---|
| Andrew Crockett | CEO | 150,000 | August 15, 2023 |
| Joanne T. Ayoob | CFO | 50,000 | September 1, 2023 |
| David A. Lewis | Director | 25,000 | June 20, 2023 |
Current Market Capitalization
The market capitalization of KalVista Pharmaceuticals, Inc. as of September 2023 stands at approximately $80 million.
Recent Stock Performance
As of September 2023, KALV is trading at approximately $10.00 per share, having shown a fluctuation of +/- 5% over the past month.
Analyst Ratings
Analyst ratings indicate a mix of perceptions regarding KALV's performance:
| Firm | Rating | Target Price ($) |
|---|---|---|
| Barclays | Outperform | 12.00 |
| Goldman Sachs | Neutral | 10.00 |
| Jefferies | Buy | 15.00 |
Shareholder Information
The shareholder structure is primarily composed of institutional and retail investors:
| Type of Shareholder | Number of Shareholders | Average Holding (Shares) |
|---|---|---|
| Institutional | 35 | 165,000 |
| Insider | 5 | 170,000 |
| Retail | 1,200 | 1,500 |
Conclusion
In summary, KalVista Pharmaceuticals, Inc. is characterized by a diverse ownership structure, predominantly held by institutional investors, with a significant presence of insiders and retail investors.
KalVista Pharmaceuticals, Inc. (KALV) Mission Statement
Core Purpose
The core purpose of KalVista Pharmaceuticals, Inc. is to provide innovative therapeutics for patients suffering from debilitating diseases, particularly focusing on ocular diseases, through cutting-edge research and development.
Strategic Objectives
- Advance clinical development of KVD824, a potential treatment for diabetic macular edema.
- Expand the pipeline to include additional indications for ocular diseases.
- Enhance partnerships for collaboration in drug development and commercialization.
Stakeholder Commitment
KalVista is committed to its stakeholders by fostering a culture of transparency, integrity, and collaboration. The company aims to:
- Deliver value to shareholders through responsible financial management.
- Engage with healthcare professionals for insights into patient needs.
- Involve patients through feedback mechanisms to tailor therapeutic solutions.
Financial Overview
As of the latest fiscal report in Q2 2023, KalVista Pharmaceuticals has reported:
| Financial Metric | Q2 2023 | Q1 2023 | Q2 2022 |
|---|---|---|---|
| Total Revenue | $2.5 million | $1.8 million | $3.1 million |
| Research and Development Expenses | $7.0 million | $6.5 million | $5.8 million |
| General and Administrative Expenses | $3.2 million | $2.9 million | $3.5 million |
| Net Loss | ($8.5 million) | ($8.0 million) | ($6.2 million) |
Innovation and Research
KalVista focuses heavily on innovation, with several active clinical trials:
- KVD824: Phase 2 clinical trial for diabetic macular edema.
- KVD001: Investigational trials for other ocular conditions.
- Collaboration with academic institutions for cutting-edge research.
Market Position
KalVista operates within a competitive landscape, targeting mainly the following market segments:
| Market Segment | Estimated Market Size (2023) | Growth Rate (2023-2028) |
|---|---|---|
| Diabetic Macular Edema | $4.5 billion | 8.5% |
| Retinal Disorders | $7.0 billion | 6.0% |
| Ocular Therapeutics | $10.2 billion | 7.3% |
Community Engagement
KalVista emphasizes social responsibility by engaging in community outreach programs, including:
- Patient education initiatives on ocular health.
- Partnerships with non-profit organizations focused on eye health.
- Funding for research into rare ocular conditions.
Conclusion of Mission Statement Elements
KalVista Pharmaceuticals, Inc. is dedicated to pioneering treatments that can significantly improve patient outcomes and drive advancements in the field of ocular therapeutics.
How KalVista Pharmaceuticals, Inc. (KALV) Works
Company Overview
KalVista Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing small molecule therapies to treat serious diseases. The company specializes in treating conditions related to the eye, particularly diabetic macular edema and other retinal diseases.
Business Model
The business model of KalVista Pharmaceuticals is centered around:
- Research and development of innovative therapeutics.
- Collaboration with other pharmaceutical companies for drug development.
- Potential licensing agreements for commercialization of therapeutic candidates.
Development Pipeline
KalVista's development pipeline includes several drug candidates targeting various diseases. The following table summarizes the key programs:
| Drug Candidate | Indication | Stage of Development | Estimated Market Size (USD) |
|---|---|---|---|
| KVD824 | Diabetic Macular Edema | Phase 2 | ~$4 billion |
| KVD001 | Retinal Disease (Wet AMD) | Phase 2 | ~$8 billion |
| KVD001 (additional indications) | Other DME indications | Preclinical | ~$3 billion |
Financial Performance
As per the latest data from Q2 2023, KalVista Pharmaceuticals reported the following financial metrics:
| Metric | Value (USD) |
|---|---|
| Total Revenue | $0 |
| Research and Development Expenses | $5.4 million |
| General and Administrative Expenses | $2.3 million |
| Net Loss for Q2 2023 | ($7.7 million) |
| Cash and Cash Equivalents | $30.2 million |
Stock Performance
As of October 2023, the stock performance of KalVista Pharmaceuticals (KALV) is as follows:
| Metric | Value |
|---|---|
| Current Stock Price (USD) | $6.50 |
| Market Capitalization (USD) | $200 million |
| 52-Week High (USD) | $8.00 |
| 52-Week Low (USD) | $4.00 |
| Average Trading Volume | 150,000 shares |
Partnerships and Collaborations
KalVista Pharmaceuticals has engaged in partnerships with various organizations to enhance its research capabilities. These include:
- Collaboration with the University of California for research on retinal diseases.
- Agreements with pharmaceutical companies for co-development of drug candidates.
- Licensing deals for specific therapeutic indications.
Regulatory Considerations
KalVista must navigate several regulatory frameworks to bring its products to market, including:
- Investigational New Drug (IND) applications with the FDA.
- Clinical trial applications in international markets.
- Compliance with Good Manufacturing Practices (GMP).
How KalVista Pharmaceuticals, Inc. (KALV) Makes Money
Revenue Streams
Revenue Streams
KalVista Pharmaceuticals, Inc. generates revenue primarily through the development and commercialization of its therapeutic products. Their focus is predominantly in the area of rare diseases, particularly through oral therapies for conditions such as hereditary angioedema (HAE).
Partnerships and Collaborations
KalVista engages in strategic partnerships with larger pharmaceutical companies to co-develop products, sharing both the financial burden and the potential revenue generated upon product approval.
Product Pipeline and Development Costs
The company’s current pipeline includes:
- KVD900 - Phase 3 for HAE
- KVD824 - Phase 2a for HAE prophylaxis
- KVD025 - Preclinical for retinal diseases
As of the latest financial statements, KalVista reported a research and development expenditure of approximately $18.3 million for the fiscal year ending April 30, 2022.
Financial Performance
For the fiscal year 2022, KalVista's total revenue was reported at $12.1 million, which is derived from collaborative agreements.
Table of Financial Overview
| Fiscal Year | Total Revenue ($ million) | R&D Expenses ($ million) | Net Loss ($ million) | Cash and Cash Equivalents ($ million) |
|---|---|---|---|---|
| 2020 | 1.5 | 16.0 | (15.2) | 34.9 |
| 2021 | 8.3 | 14.9 | (7.9) | 30.1 |
| 2022 | 12.1 | 18.3 | (10.6) | 24.5 |
Market Potential and Growth Projections
The global hereditary angioedema market is projected to grow significantly. Reports indicate a market size of $3.4 billion by 2026. KalVista aims to capture a substantial share through its robust pipeline.
Grants and Funding
KalVista has also received grants from the National Institutes of Health (NIH) and other agencies, contributing to their research funding. In 2021, they secured a grant totaling $1.2 million for the development of new treatments.
Investment and Share Performance
KalVista Pharmaceuticals, Inc. went public in 2016, with an initial public offering (IPO) at $12.00 per share. As of October 2023, the share price fluctuates around $8.50, reflecting market conditions and company performance.
Intellectual Property and Licensing
KalVista holds several patents related to its medications, providing a competitive advantage and potential licensing revenue. In 2022, the company generated $2.5 million through licensing agreements.
Clinical Trials and Regulatory Milestones
The success of KalVista’s products in clinical trials is pivotal to its financial health. Positive results can lead to partnerships and increased funding.
Cost Management Strategy
KalVista aims to maintain a disciplined approach to cost management, with a projected operating expense reduction of 10% year-over-year, focusing on streamlining operations without compromising R&D.
Overall Financial Health
As of the latest reports, KalVista holds total assets of approximately $39 million against total liabilities of about $18 million, indicating a solid financial footing.
KalVista Pharmaceuticals, Inc. (KALV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support